Neuropharmacologists examine how drugs interact with the nervous system, focusing on their effects on receptors, neurotransmitters, and enzymes in the brain. Their work is crucial in developing treatments for neurological disorders such as depression, anxiety, schizophrenia, and Parkinson’s disease. By understanding the pharmacodynamics of drugs—how they affect brain function—neuropharmacologists explore ways to enhance or inhibit specific neurochemical pathways to treat these conditions. Additionally, they study pharmacokinetics, which involves understanding how drugs are absorbed, metabolized, and eliminated by the body, to optimize drug dosages and reduce side effects. Neuropharmacologists are instrumental in advancing drug development, identifying new therapeutic targets, and designing medications with improved efficacy and fewer adverse reactions. Their expertise extends into addiction medicine, as they investigate how substances of abuse impact the brain and contribute to dependence and withdrawal symptoms. By conducting rigorous clinical trials, neuropharmacologists assess the safety and effectiveness of new medications, ensuring that patients receive the best possible treatments tailored to their needs.
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : In silico in vitro and in vivo study of geraniol role in Alzheimer's disease
Bhuvanesh Baniya, Mohanlal Sukhadia University, India
Title : Prince transform: a wave-mechanical framework for real-time EEG analysis and early seizure prediction using chirp and drift detection
Mustafa A Khan, Sevaro Health Inc., United States
Title : Gut-brain axis in autism spectrum disorder: MicroRNAs as a critical mediator of pathogenesis
Rahem Rahmati, Shahrekord University of Medical Sciences, Iran (Islamic Republic of)